Brazil grants patent for VAL001
The Brazilian National Institute of Industrial Property (INPI) has announced the intent to grant Respiratorius patent for VAL001.After the formal fees have been paid, the patent will be granted, which will give Respiratorius market exclusivity in Brazil until 2031. Previously, the patent has been granted in Europe, US, Japan, Canada, and Korea under equivalent conditions. The patent covers a combination of an HDAC inhibitor and a steroid for pre-treatment with standard chemotherapy (R-CHOP) in the treatment of diffuse large B-cell lymphoma (DLBCL), a lymphoma which annually affects about